CHAPTER 1. Industry Overview of Systemic Lupus Erythematosus Market
1.1. Definition and Scope
1.1.1. Definition of Systemic Lupus Erythematosus
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Systemic Lupus Erythematosus Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Systemic Lupus Erythematosus Market By Drug Classes
1.2.3. Systemic Lupus Erythematosus Market By Route of Administration
1.2.4. Systemic Lupus Erythematosus Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Systemic Lupus Erythematosus Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Systemic Lupus Erythematosus Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2021
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Systemic Lupus Erythematosus Market By Drug Classes
4.1. Introduction
4.2. Systemic Lupus Erythematosus Revenue By Drug Classes
4.2.1. Systemic Lupus Erythematosus Revenue (USD Million) and Forecast, By Drug Classes, 2018-2030
4.2.2. NSAIDs
4.2.2.1. NSAIDs Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.3. Antimalarials
4.2.3.1. Antimalarials Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.4. Corticosteroids
4.2.4.1. Corticosteroids Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.5. Immunosuppressants
4.2.5.1. Immunosuppressants Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.6. Biologics
4.2.6.1. Biologics Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 5. Systemic Lupus Erythematosus Market By Route of Administration
5.1. Introduction
5.2. Systemic Lupus Erythematosus Revenue By Route of Administration
5.2.1. Systemic Lupus Erythematosus Revenue (USD Million) and Forecast, By Route of Administration, 2018-2030
5.2.2. Oral
5.2.2.1. Oral Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.3. Intravenous
5.2.3.1. Intravenous Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.4. Subcutaneous
5.2.4.1. Subcutaneous Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 6. North America Systemic Lupus Erythematosus Market By Country
6.1. North America Systemic Lupus Erythematosus Market Overview
6.2. U.S.
6.2.1. U.S. Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
6.2.2. U.S. Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
6.3. Canada
6.3.1. Canada Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
6.3.2. Canada Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
6.4. North America PEST Analysis
CHAPTER 7. Europe Systemic Lupus Erythematosus Market By Country
7.1. Europe Systemic Lupus Erythematosus Market Overview
7.2. U.K.
7.2.1. U.K. Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
7.2.2. U.K. Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
7.3. Germany
7.3.1. Germany Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
7.3.2. Germany Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
France
7.3.3. France Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
7.3.4. France Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
7.4. Spain
7.4.1. Spain Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
7.4.2. Spain Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
7.5. Rest of Europe
7.5.1. Rest of Europe Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
7.5.2. Rest of Europe Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
7.6. Europe PEST Analysis
CHAPTER 8. Asia Pacific Systemic Lupus Erythematosus Market By Country
8.1. Asia Pacific Systemic Lupus Erythematosus Market Overview
8.2. China
8.2.1. China Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
8.2.2. China Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
8.3. Japan
8.3.1. Japan Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
8.3.2. Japan Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
8.4. India
8.4.1. India Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
8.4.2. India Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
8.5. Australia
8.5.1. Australia Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
8.5.2. Australia Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
8.6. South Korea
8.6.1. South Korea Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
8.6.2. South Korea Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
8.7. Rest of Asia-Pacific
8.7.1. Rest of Asia-Pacific Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
8.7.2. Rest of Asia-Pacific Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
8.8. Asia Pacific PEST Analysis
CHAPTER 9. Latin America Systemic Lupus Erythematosus Market By Country
9.1. Latin America Systemic Lupus Erythematosus Market Overview
9.2. Brazil
9.2.1. Brazil Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
9.2.2. Brazil Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
9.3. Mexico
9.3.1. Mexico Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
9.3.2. Mexico Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
9.4. Rest of Latin America
9.4.1. Rest of Latin America Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
9.4.2. Rest of Latin America Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
9.5. Latin America PEST Analysis
CHAPTER 10. Middle East & Africa Systemic Lupus Erythematosus Market By Country
10.1. Middle East & Africa Systemic Lupus Erythematosus Market Overview
10.2. GCC
10.2.1. GCC Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
10.2.2. GCC Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
10.3. South Africa
10.3.1. South Africa Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
10.3.2. South Africa Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
10.4. Rest of Middle East & Africa
10.4.1. Rest of Middle East & Africa Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Drug Classes, 2018-2030
10.4.2. Rest of Middle East & Africa Systemic Lupus Erythematosus Revenue (USD Million) and Forecast By Route of Administration, 2018-2030
10.5. Middle East & Africa PEST Analysis
CHAPTER 11. Player Analysis Of Systemic Lupus Erythematosus Market
11.1. Systemic Lupus Erythematosus Market Company Share Analysis
11.2. Competition Matrix
11.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2. New Product Launches and Product Enhancements
11.2.3. Mergers And Acquisition In Global Systemic Lupus Erythematosus Market
11.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 12. Company Profile
12.1. Roche
12.1.1. Company Snapshot
12.1.2. Business Overview
12.1.3. Financial Overview
12.1.3.1. Revenue (USD Million), 2021
12.1.3.2. Roche 2021 Systemic Lupus Erythematosus Business Regional Distribution
12.1.4. Product/Service and Specification
12.1.5. Recent Developments & Business Strategy
12.2. Sanofi
12.3. GlaxoSmithKline
12.4. Pfizer
12.5. Bayer
12.6. Astra Zeneca
12.7. Novartis
12.8. ImmuPharma
12.9. Aurinia Pharmaceuticals
The estimated value of global systemic lupus erythematosus market in 2021 was accounted to be USD 1,951 Million.
The projected CAGR systemic lupus erythematosus market during the analysis period of 2022 to 2030 is 7%.
The prominent players of the global systemic lupus erythematosus market are Roche, Sanofi, GlaxoSmithKline, Pfizer, Bayer, Astra Zeneca, Novartis, ImmuPharma, and Aurinia Pharmaceuticals.
North America held the dominating systemic lupus erythematosus during the analysis period of 2022 to 2030.
Asia-Pacific region exhibited fastest growing CAGR for systemic lupus erythematosus during the analysis period of 2022 to 2030.
Rapid spread of systemic lupus erythematosus diseases and growing geriatric population drives the growth of global systemic lupus erythematosus market.
Based on drug classes, immunosuppressants segment is expected to hold the maximum share of the systemic lupus erythematosus market.
Customer Satisfaction
Availability - we are always there when you need us
Fortune 50 Companies trust Acumen Research and Consulting
of our reports are exclusive and first in the industry
more data and analysis
reports published till date